{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,25]],"date-time":"2026-10-25T11:59:56Z","timestamp":1792929596763,"version":"4.5.0"},"reference-count":55,"publisher":"IMR Press","issue":"4","license":[{"start":{"date-parts":[[2026,8,5]],"date-time":"2026-08-05T00:00:00Z","timestamp":1785888000000},"content-version":"unspecified","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Alpha Psychiatry"],"DOI":"10.31083\/ap52026","type":"journal-article","created":{"date-parts":[[2026,9,3]],"date-time":"2026-09-03T12:23:51Z","timestamp":1788438231000},"source":"Crossref","is-referenced-by-count":1,"title":["Glutamatergic Modulators in Schizophrenia: Are We Ready to Move Beyond the Narrow Focus on Dopamine? A Potential Paradigm Shift in Psychopharmacology"],"prefix":"10.31083","volume":"27","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-6928-1224","authenticated-orcid":true,"given":"Renato","family":"de Filippis","sequence":"first","affiliation":[{"name":"Psychiatry Unit, Department of Health Sciences, University Magna Graecia of Catanzaro, 88100 Catanzaro, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5078-6716","authenticated-orcid":true,"given":"Daniel","family":"Guinart","sequence":"additional","affiliation":[{"name":"Institut de Salut Mental, Hospital del Mar, 08003 Barcelona, Spain"},{"name":"Hospital del Mar Research Institute, CIBERSAM, 08003 Barcelona, Spain"},{"name":"Department of Psychiatry and Molecular Medicine, Donald and Barbara Zucker School of Medicine at Hofstra\/Northwell, Hempstead, NY 11549, USA"},{"name":"Center for the Promotion of Interdisciplinary Research in Medicine and Life Science (PIRMS), Keio University School of Medicine, 160-8582 Tokyo, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7254-5646","authenticated-orcid":true,"given":"Christoph U.","family":"Correll","sequence":"additional","affiliation":[{"name":"Department of Psychiatry and Molecular Medicine, Donald and Barbara Zucker School of Medicine at Hofstra\/Northwell, Hempstead, NY 11549, USA"},{"name":"Northwell, New Hyde Park, New York, NY 11040, USA"},{"name":"Department of Child and Adolescent Psychiatry, Universit\u00e4tsmedizin Charit\u00e9 Berlin, 10117 Berlin, Germany"},{"name":"German Center for Mental Health (DZPG), Partner Site Berlin, 10117 Berlin, Germany"},{"name":"Einstein Center for Youth Mental Health (ECYM), 13353 Berlin, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gaspare","family":"Liparota","sequence":"additional","affiliation":[{"name":"Psychiatry Unit, Department of Health Sciences, University Magna Graecia of Catanzaro, 88100 Catanzaro, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Taishiro","family":"Kishimoto","sequence":"additional","affiliation":[{"name":"Center for the Promotion of Interdisciplinary Research in Medicine and Life Science (PIRMS), Keio University School of Medicine, 160-8582 Tokyo, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5375-3565","authenticated-orcid":true,"given":"Pasquale","family":"De Fazio","sequence":"additional","affiliation":[{"name":"Psychiatry Unit, Department of Health Sciences, University Magna Graecia of Catanzaro, 88100 Catanzaro, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"16242","published-online":{"date-parts":[[2026,8,5]]},"reference":[{"key":"ref1","doi-asserted-by":"publisher","unstructured":"Kahn RS, Sommer IE, Murray RM, Meyer-Lindenberg A, Weinberger DR, Cannon TD, et al. Schizophrenia. Nature Reviews. Disease Primers. 2015; 1: 15067.","DOI":"10.1038\/nrdp.2015.67"},{"key":"ref2","doi-asserted-by":"publisher","unstructured":"Yang Z, Lee SH, Abdul Rashid NA, See YM, Dauwels J, Tan BL, et al. Predicting Real-World Functioning in Schizophrenia: The Relative Contributions of Neurocognition, Functional Capacity, and Negative Symptoms. Frontiers in Psychiatry. 2021; 12: 639536.","DOI":"10.3389\/fpsyt.2021.639536"},{"key":"ref3","doi-asserted-by":"publisher","unstructured":"Miyamoto S, Miyake N, Jarskog LF, Fleischhacker WW, Lieberman JA. Pharmacological treatment of schizophrenia: a critical review of the pharmacology and clinical effects of current and future therapeutic agents. Molecular Psychiatry. 2012; 17: 1206\u20131227.","DOI":"10.1038\/mp.2012.47"},{"key":"ref4","doi-asserted-by":"publisher","unstructured":"Howes OD, Kapur S. The dopamine hypothesis of schizophrenia: version III--the final common pathway. Schizophrenia Bulletin. 2009; 35: 549\u2013562.","DOI":"10.1093\/schbul\/sbp006"},{"key":"ref5","doi-asserted-by":"publisher","unstructured":"Feber L, Peter NL, Chiocchia V, Schneider-Thoma J, Siafis S, Bighelli I, et al. Antipsychotic Drugs and Cognitive Function: A Systematic Review and Network Meta-Analysis. JAMA Psychiatry. 2025; 82: 47\u201356.","DOI":"10.1001\/jamapsychiatry.2024.2890"},{"key":"ref6","doi-asserted-by":"publisher","unstructured":"Green MF, Horan WP, Lee J. Social cognition in schizophrenia. Nature Reviews. Neuroscience. 2015; 16: 620\u2013631.","DOI":"10.1038\/nrn4005"},{"key":"ref7","doi-asserted-by":"publisher","unstructured":"Adell A. What value do NMDA receptor antagonist models of schizophrenia have for novel drug discovery? Expert Opinion on Drug Discovery. 2025; 20: 1377\u20131385.","DOI":"10.1080\/17460441.2025.2562017"},{"key":"ref8","doi-asserted-by":"publisher","unstructured":"Coyle JT. NMDA receptor and schizophrenia: a brief history. Schizophrenia Bulletin. 2012; 38: 920\u2013926.","DOI":"10.1093\/schbul\/sbs076"},{"key":"ref9","doi-asserted-by":"publisher","unstructured":"Pei JC, Hung WL, Lin BX, Shih MH, Lu LY, Luo DZ, et al. Therapeutic potential and underlying mechanism of sarcosine (N-methylglycine) in N-methyl-D-aspartate (NMDA) receptor hypofunction models of schizophrenia. Journal of Psychopharmacology (Oxford, England). 2019; 33: 1288\u20131302.","DOI":"10.1177\/0269881119856558"},{"key":"ref10","doi-asserted-by":"publisher","unstructured":"Lisman JE, Coyle JT, Green RW, Javitt DC, Benes FM, Heckers S, et al. Circuit-based framework for understanding neurotransmitter and risk gene interactions in schizophrenia. Trends in Neurosciences. 2008; 31: 234\u2013242.","DOI":"10.1016\/j.tins.2008.02.005"},{"key":"ref11","doi-asserted-by":"publisher","unstructured":"Dienel SJ, Schoonover KE, Lewis DA. Cognitive Dysfunction and Prefrontal Cortical Circuit Alterations in Schizophrenia: Developmental Trajectories. Biological Psychiatry. 2022; 92: 450\u2013459.","DOI":"10.1016\/j.biopsych.2022.03.002"},{"key":"ref12","doi-asserted-by":"publisher","unstructured":"Fadgyas-Stanculete M, Capatina OO. Glutamate-Based Therapeutic Strategies for Schizophrenia: Emerging Approaches Beyond Dopamine. International Journal of Molecular Sciences. 2025; 26: 4331.","DOI":"10.3390\/ijms26094331"},{"key":"ref13","doi-asserted-by":"publisher","unstructured":"Egerton A, Grace AA, Stone J, Bossong MG, Sand M, McGuire P. Glutamate in schizophrenia: Neurodevelopmental perspectives and drug development. Schizophrenia Research. 2020; 223: 59\u201370.","DOI":"10.1016\/j.schres.2020.09.013"},{"key":"ref14","doi-asserted-by":"publisher","unstructured":"Aloi M, de Filippis R, Carbone EA, Rania M, Bertuca A, Golia M, et al. Latent profile analysis identifies four different clinical schizophrenia profiles through aberrant salience. Schizophrenia (Heidelberg, Germany). 2024; 10: 93.","DOI":"10.1038\/s41537-024-00514-9"},{"key":"ref15","doi-asserted-by":"publisher","unstructured":"Corlett PR, Fraser KM. 20 Years of Aberrant Salience in Psychosis: What Have We Learned? The American Journal of Psychiatry. 2025; 182: 819\u2013829.","DOI":"10.1176\/appi.ajp.20240556"},{"key":"ref16","doi-asserted-by":"publisher","unstructured":"Javitt DC, Zukin SR. Recent advances in the phencyclidine model of schizophrenia. The American Journal of Psychiatry. 1991; 148: 1301\u20131308.","DOI":"10.1176\/ajp.148.10.1301"},{"key":"ref17","doi-asserted-by":"publisher","unstructured":"Hu W, MacDonald ML, Elswick DE, Sweet RA. The glutamate hypothesis of schizophrenia: evidence from human brain tissue studies. Annals of the New York Academy of Sciences. 2015; 1338: 38\u201357.","DOI":"10.1111\/nyas.12547"},{"key":"ref18","doi-asserted-by":"publisher","unstructured":"Balu DT. The NMDA Receptor and Schizophrenia: From Pathophysiology to Treatment. Advances in pharmacology (San Diego, Calif.). 2016; 76: 351\u2013382.","DOI":"10.1016\/bs.apha.2016.01.006"},{"key":"ref19","doi-asserted-by":"publisher","unstructured":"Fabbri C, Serretti A. Role of 108 schizophrenia-associated loci in modulating psychopathological dimensions in schizophrenia and bipolar disorder. American Journal of Medical Genetics. Part B, Neuropsychiatric Genetics: the Official Publication of the International Society of Psychiatric Genetics. 2017; 174: 757\u2013764.","DOI":"10.1002\/ajmg.b.32577"},{"key":"ref20","doi-asserted-by":"publisher","unstructured":"Fromer M, Roussos P, Sieberts SK, Johnson JS, Kavanagh DH, Perumal TM, et al. Gene expression elucidates functional impact of polygenic risk for schizophrenia. Nature Neuroscience. 2016; 19: 1442\u20131453.","DOI":"10.1038\/nn.4399"},{"key":"ref21","doi-asserted-by":"publisher","unstructured":"Cohen SM, Tsien RW, Goff DC, Halassa MM. The impact of NMDA receptor hypofunction on GABAergic neurons in the pathophysiology of schizophrenia. Schizophrenia Research. 2015; 167: 98\u2013107.","DOI":"10.1016\/j.schres.2014.12.026"},{"key":"ref22","doi-asserted-by":"publisher","unstructured":"Dong B, Yue Y, Dong H, Wang Y. N-methyl-D-aspartate receptor hypofunction as a potential contributor to the progression and manifestation of many neurological disorders. Frontiers in Molecular Neuroscience. 2023; 16: 1174738.","DOI":"10.3389\/fnmol.2023.1174738"},{"key":"ref23","doi-asserted-by":"publisher","unstructured":"Merritt K, McGuire P, Egerton A. Relationship between Glutamate Dysfunction and Symptoms and Cognitive Function in Psychosis. Frontiers in Psychiatry. 2013; 4: 151.","DOI":"10.3389\/fpsyt.2013.00151"},{"key":"ref24","doi-asserted-by":"publisher","unstructured":"Liang CW, Cheng HY, Tseng MCM. Effects of sodium benzoate on cognitive function in neuropsychiatric disorders: a systematic review and meta-analysis. Frontiers in Psychiatry. 2024; 15: 1370431.","DOI":"10.3389\/fpsyt.2024.1370431"},{"key":"ref25","doi-asserted-by":"publisher","unstructured":"Lane HY, Lin CH, Green MF, Hellemann G, Huang CC, Chen PW, et al. Add-on treatment of benzoate for schizophrenia: a randomized, double-blind, placebo-controlled trial of D-amino acid oxidase inhibitor. JAMA Psychiatry. 2013; 70: 1267\u20131275.","DOI":"10.1001\/jamapsychiatry.2013.2159"},{"key":"ref26","doi-asserted-by":"publisher","unstructured":"Terry-Lorenzo RT, Fan RH, Khin NA, Singh JB. Therapeutic potential of D-amino acid oxidase inhibitors for cognitive impairment associated with schizophrenia: learnings from luvadaxistat. The International Journal of Neuropsychopharmacology. 2024; 28: pyae066.","DOI":"10.1093\/ijnp\/pyae066"},{"key":"ref27","doi-asserted-by":"publisher","unstructured":"Meftah A, Hasegawa H, Kantrowitz JT. D-Serine: A Cross Species Review of Safety. Frontiers in Psychiatry. 2021; 12: 726365.","DOI":"10.3389\/fpsyt.2021.726365"},{"key":"ref28","doi-asserted-by":"publisher","unstructured":"Guercio GD, Panizzutti R. Potential and Challenges for the Clinical Use of d-Serine As a Cognitive Enhancer. Frontiers in Psychiatry. 2018; 9: 14.","DOI":"10.3389\/fpsyt.2018.00014"},{"key":"ref29","doi-asserted-by":"publisher","unstructured":"Kantrowitz JT, Woods SW, Petkova E, Cornblatt B, Corcoran CM, Chen H, et al. D-serine for the treatment of negative symptoms in individuals at clinical high risk of schizophrenia: a pilot, double-blind, placebo-controlled, randomised parallel group mechanistic proof-of-concept trial. The Lancet. Psychiatry. 2015; 2: 403\u2013412.","DOI":"10.1016\/S2215-0366(15)00098-X"},{"key":"ref30","doi-asserted-by":"publisher","unstructured":"Datta A, Rana H, Singh S, Singh TG. Targeting neurochemical and immune dysregulation in schizophrenia: From molecular mechanisms to emerging therapeutic strategies. Progress in Neuro-psychopharmacology & Biological Psychiatry. 2025; 143: 111535.","DOI":"10.1016\/j.pnpbp.2025.111535"},{"key":"ref31","doi-asserted-by":"publisher","unstructured":"Baeissa AA. Emerging Innovations in Third- and Fourth-Generation Antipsychotics: Mechanistic Advances and Clinical Implications. Psychopharmacology Bulletin. 2026; 56: 112\u2013125.","DOI":"10.64719\/pb.15431"},{"key":"ref32","doi-asserted-by":"publisher","unstructured":"Liang CW, Cheng HY, Tseng MCM. Augmentation with glutamatergic modulators for schizophrenia: A network meta-analysis. Progress in Neuro-psychopharmacology & Biological Psychiatry. 2025; 142: 111495.","DOI":"10.1016\/j.pnpbp.2025.111495"},{"key":"ref33","doi-asserted-by":"publisher","unstructured":"Ji T, Yu B, Ma R. Cerebellar-cortical dysfunction and schizophrenia: Advances in neurocognition and therapeutic strategies. Schizophrenia Research. 2025; 286: 37\u201346.","DOI":"10.1016\/j.schres.2025.10.015"},{"key":"ref34","doi-asserted-by":"publisher","unstructured":"de Filippis R, Carbone EA, Rania M, Aloi M, Segura-Garcia C, De Fazio P. Applying a clinical staging model in patients affected by schizophrenia spectrum disorder. Frontiers in Psychiatry. 2024; 15: 1387913.","DOI":"10.3389\/fpsyt.2024.1387913"},{"key":"ref35","doi-asserted-by":"publisher","unstructured":"Kantrowitz JT, Malhotra AK, Cornblatt B, Silipo G, Balla A, Suckow RF, et al. High dose D-serine in the treatment of schizophrenia. Schizophrenia Research. 2010; 121: 125\u2013130.","DOI":"10.1016\/j.schres.2010.05.012"},{"key":"ref36","doi-asserted-by":"publisher","unstructured":"Buben\u00edkov\u00e1-Valesov\u00e1 V, Hor\u00e1cek J, Vrajov\u00e1 M, H\u00f6schl C. Models of schizophrenia in humans and animals based on inhibition of NMDA receptors. Neuroscience and Biobehavioral Reviews. 2008; 32: 1014\u20131023.","DOI":"10.1016\/j.neubiorev.2008.03.012"},{"key":"ref37","doi-asserted-by":"publisher","unstructured":"Cadinu D, Grayson B, Podda G, Harte MK, Doostdar N, Neill JC. NMDA receptor antagonist rodent models for cognition in schizophrenia and identification of novel drug treatments, an update. Neuropharmacology. 2018; 142: 41\u201362.","DOI":"10.1016\/j.neuropharm.2017.11.045"},{"key":"ref38","doi-asserted-by":"publisher","unstructured":"Saleh Y, Jarratt-Barnham I, Petitet P, Fernandez-Egea E, Manohar SG, Husain M. Negative symptoms and cognitive impairment are associated with distinct motivational deficits in treatment resistant schizophrenia. Molecular Psychiatry. 2023; 28: 4831\u20134841.","DOI":"10.1038\/s41380-023-02232-7"},{"key":"ref39","doi-asserted-by":"publisher","unstructured":"Hird EJ, Diederen K, Leucht S, Jensen KB, McGuire P. The Placebo Effect in Psychosis: Why It Matters and How to Measure It. Biological Psychiatry Global Open Science. 2023; 3: 605\u2013613.","DOI":"10.1016\/j.bpsgos.2023.02.008"},{"key":"ref40","doi-asserted-by":"publisher","unstructured":"Hu N, Li W, Deng H, Song J, Yang H, Chai J, et al. The mediating role of negative symptoms in \"secondary factors\" determining social functioning in chronic schizophrenia. Frontiers in Psychiatry. 2023; 14: 1196760.","DOI":"10.3389\/fpsyt.2023.1196760"},{"key":"ref41","doi-asserted-by":"publisher","unstructured":"Paz RD, Tardito S, Atzori M, Tseng KY. Glutamatergic dysfunction in schizophrenia: from basic neuroscience to clinical psychopharmacology. European Neuropsychopharmacology: the Journal of the European College of Neuropsychopharmacology. 2008; 18: 773\u2013786.","DOI":"10.1016\/j.euroneuro.2008.06.005"},{"key":"ref42","doi-asserted-by":"publisher","unstructured":"Guinart D, Fagiolini A, Fusar-Poli P, Giordano GM, Leucht S, Moreno C, et al. On the Road to Individualizing Pharmacotherapy for Adolescents and Adults with Schizophrenia - Results from an Expert Consensus Following the Delphi Method. Neuropsychiatric Disease and Treatment. 2024; 20: 1139\u20131152.","DOI":"10.2147\/NDT.S456163"},{"key":"ref43","doi-asserted-by":"publisher","unstructured":"Merritt K, Egerton A, Kempton MJ, Taylor MJ, McGuire PK. Nature of Glutamate Alterations in Schizophrenia: A Meta-analysis of Proton Magnetic Resonance Spectroscopy Studies. JAMA Psychiatry. 2016; 73: 665\u2013674.","DOI":"10.1001\/jamapsychiatry.2016.0442"},{"key":"ref44","doi-asserted-by":"publisher","unstructured":"Egerton A, Stone JM, Chaddock CA, Barker GJ, Bonoldi I, Howard RM, et al. Relationship between brain glutamate levels and clinical outcome in individuals at ultra high risk of psychosis. Neuropsychopharmacology: Official Publication of the American College of Neuropsychopharmacology. 2014; 39: 2891\u20132899.","DOI":"10.1038\/npp.2014.143"},{"key":"ref45","doi-asserted-by":"publisher","unstructured":"Javitt DC, Steinschneider M, Schroeder CE, Arezzo JC. Role of cortical N-methyl-D-aspartate receptors in auditory sensory memory and mismatch negativity generation: implications for schizophrenia. Proceedings of the National Academy of Sciences of the United States of America. 1996; 93: 11962\u201311967.","DOI":"10.1073\/pnas.93.21.11962"},{"key":"ref46","doi-asserted-by":"publisher","unstructured":"Javitt DC, Sweet RA. Auditory dysfunction in schizophrenia: integrating clinical and basic features. Nature Reviews. Neuroscience. 2015; 16: 535\u2013550.","DOI":"10.1038\/nrn4002"},{"key":"ref47","doi-asserted-by":"publisher","unstructured":"Harrison PJ, Weinberger DR. Schizophrenia genes, gene expression, and neuropathology: on the matter of their convergence. Molecular Psychiatry. 2005; 10: 40\u201368; image 5.","DOI":"10.1038\/sj.mp.4001558"},{"key":"ref48","doi-asserted-by":"publisher","unstructured":"Dalvie S, Horn N, Nossek C, van der Merwe L, Stein DJ, Ramesar R. Psychosis and relapse in bipolar disorder are related to GRM3, DAOA, and GRIN2B genotype. African Journal of Psychiatry. 2010; 13: 297\u2013301.","DOI":"10.4314\/ajpsy.v13i4.61880"},{"key":"ref49","doi-asserted-by":"publisher","unstructured":"Guinart D, de Filippis R, Rosson S, Patil B, Prizgint L, Talasazan N, et al. Development and Validation of a Computerized Adaptive Assessment Tool for Discrimination and Measurement of Psychotic Symptoms. Schizophrenia Bulletin. 2021; 47: 644\u2013652.","DOI":"10.1093\/schbul\/sbaa168"},{"key":"ref50","doi-asserted-by":"publisher","unstructured":"Kishimoto T. Will digital technology address the challenges of drug development in psychiatry? World Psychiatry: Official Journal of the World Psychiatric Association (WPA). 2023; 22: 79\u201380.","DOI":"10.1002\/wps.21063"},{"key":"ref51","doi-asserted-by":"publisher","unstructured":"Luessen DJ, Conn PJ. Allosteric Modulators of Metabotropic Glutamate Receptors as Novel Therapeutics for Neuropsychiatric Disease. Pharmacological Reviews. 2022; 74: 630\u2013661.","DOI":"10.1124\/pharmrev.121.000540"},{"key":"ref52","doi-asserted-by":"publisher","unstructured":"Ellaithy A, Younkin J, Gonz\u00e1lez-Maeso J, Logothetis DE. Positive allosteric modulators of metabotropic glutamate 2 receptors in schizophrenia treatment. Trends in Neurosciences. 2015; 38: 506\u2013516.","DOI":"10.1016\/j.tins.2015.06.002"},{"key":"ref53","doi-asserted-by":"publisher","unstructured":"Insel TR. The NIMH experimental medicine initiative. World Psychiatry: Official Journal of the World Psychiatric Association (WPA). 2015; 14: 151\u2013153.","DOI":"10.1002\/wps.20227"},{"key":"ref54","doi-asserted-by":"publisher","unstructured":"Thall PF. Adaptive Enrichment Designs in Clinical Trials. Annual Review of Statistics and its Application. 2021; 8: 393\u2013411.","DOI":"10.1146\/annurev-statistics-040720-032818"},{"key":"ref55","doi-asserted-by":"publisher","unstructured":"Kahn RS, Sommer IE. The neurobiology and treatment of first-episode schizophrenia. Molecular Psychiatry. 2015; 20: 84\u201397.","DOI":"10.1038\/mp.2014.66"}],"container-title":["Alpha Psychiatry"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.imrpress.com\/journal\/AP\/27\/4\/10.31083\/AP52026","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,9,3]],"date-time":"2026-09-03T12:24:26Z","timestamp":1788438266000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.imrpress.com\/journal\/AP\/27\/4\/10.31083\/AP52026"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,8,5]]},"references-count":55,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2026]]}},"alternative-id":["S2757-8038(26)02189-0"],"URL":"https:\/\/doi.org\/10.31083\/ap52026","relation":{},"ISSN":["2757-8038"],"issn-type":[{"value":"2757-8038","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,8,5]]},"article-number":"52026"}}